Supernus Pharmaceuticals reported record third quarter 2026 revenues and positive net income, announced FDA orphan-drug exclusivity for ONAPGO, and is progressing with a pending merger with Indivior Pharmaceuticals. The merger is expected to create a combined CNS-focused company with expanded capabilities. The company continues to collaborate with Biogen for commercialization of ZURZUVAE for postpartum depression.

• Supernus Pharmaceuticals reported record third quarter 2026 revenues of $226.8 million [N1].
• The company reported net income of $20.9 million and basic EPS of $0.36 for Q3 2026 [S2].
• Supernus Pharmaceuticals beat Q3 earnings and revenue expectations as reported [N2].
• The FDA recognized seven years of orphan-drug exclusivity for ONAPGO, enhancing market protection [N6].
• Supernus and Indivior announced a merger agreement to create a $2.2 billion CNS company, with shares surging in pre-market trading [N8].

Supernus has demonstrated record revenue growth and profitability in recent quarters, supported by a diversified CNS product portfolio and strategic collaborations. The pending merger with Indivior broadens its operational scale. FDA recognition of orphan-drug exclusivity for ONAPGO and the commercial launch of ZURZUVAE as the first oral treatment for postpartum depression represent significant milestones. Strong liquidity and cash reserves provide financial flexibility to support ongoing development and commercialization efforts.

Supernus faces risks from its dependence on third-party collaborators for development, manufacturing, and commercialization, which could be disrupted or terminated. Regulatory compliance challenges and healthcare reform policies may impact pricing and reimbursement. The pending merger carries risks including potential delays, failure to complete, integration challenges, and litigation that could divert management attention and resources. Post-merger financial leverage may constrain operational flexibility. Market acceptance of new products like ZURZUVAE may be limited by safety warnings and reimbursement restrictions.

Supernus Pharmaceuticals' moat is supported by its portfolio of approved CNS treatments and collaborations with established pharmaceutical companies such as Biogen, which provide commercialization capabilities and market access. The company's intellectual property rights and supply agreements for key products like APOKYN and ONAPGO contribute to its competitive position. FDA approval and orphan-drug exclusivity for products such as ZURZUVAE enhance market protection. However, reliance on third-party collaborators and suppliers introduces execution risks that could affect sustained competitive advantage.

• Merger Completion Risks: The merger with Indivior is subject to regulatory approvals and customary conditions that may not be satisfied, causing delays or failure to complete. Failure to complete the merger could materially adversely affect Supernus' business and stock price [S2].
• Collaborator Dependence: Supernus relies on third-party collaborators such as Biogen for commercialization and on suppliers like Britannia for product supply. Termination or failure of these relationships could impair development, manufacturing, and sales [S1].
• Regulatory and Compliance Risks: The company is subject to healthcare reform laws and regulatory requirements that may change, potentially impacting pricing, reimbursement, and operations. FDA and foreign regulatory approvals are required for product commercialization [S1].
• Litigation Related to Merger: Shareholder lawsuits have been filed alleging misrepresentation in merger disclosures, seeking injunctions and damages, which could delay or prevent merger completion and impose costs [S2].
• Financial Leverage Post-Merger: The combined company is expected to have significant indebtedness and covenants that may limit financial and operating flexibility, affecting investment and strategic opportunities [S2].
• Market Acceptance and Competition: Products like ZURZUVAE face risks of limited market acceptance due to safety warnings, reimbursement restrictions, and competition from existing or future therapies [S1].

• Supernus Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products for central nervous system (CNS) diseases including ADHD, Parkinson's Disease, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea [S2].
• The company has a diverse neuroscience portfolio with approved treatments and a pipeline of novel CNS product candidates [S2].
• Supernus entered into a merger agreement with Indivior Pharmaceuticals, Inc. in August 2026, which upon completion will create a combined company named Supernus, Inc. with shares continuing to trade under ticker SUPN [S2].
• The merger consideration involves an exchange ratio of 1.5401 Indivior shares per Supernus share, fixed and not subject to market price adjustments [S2].
• The merger is subject to customary regulatory approvals and conditions, with risks including potential delays, failure to complete, and integration challenges [S2].
• Supernus reported record third quarter 2026 revenues of $226.8 million [N1].
• For the quarter ended September 30, 2026, Supernus reported net income of $20.9 million and basic earnings per share of $0.36 [S2].
• As of September 30, 2026, Supernus had cash and cash equivalents of $175.9 million and a current ratio of 2.49, indicating strong liquidity [S2].
• Supernus collaborates with partners such as Biogen for commercialization of products like ZURZUVAE (zuranolone) for postpartum depression in the U.S. [S1].
• ZURZUVAE was FDA approved in August 2023 and became commercially available in December 2023 as the first oral treatment specifically indicated for adults with PPD [S1].
• The company faces risks related to reliance on collaborators for development, manufacturing, and commercialization, including potential termination or failure of collaborations [S1].
• Supernus has intellectual property and supply agreements with third parties such as Britannia for products APOKYN and ONAPGO, with risks related to supply termination and lack of technology transfer assistance [S1].
• The company is subject to regulatory risks including compliance with healthcare reform laws and potential impacts from executive orders aimed at lowering pharmaceutical prices [S1].
• Supernus faces litigation risks related to the pending merger, including shareholder lawsuits alleging misrepresentation and seeking injunctions or damages [S2].
• The combined company post-merger is expected to have a leveraged balance sheet with significant financing obligations that may limit financial flexibility [S2].
• Supernus reported quarterly revenue of $94.98 million as of Q1 2020, indicating historical revenue disclosure [S2].
• The company’s recent news coverage includes multiple reports on earnings results, merger developments, FDA exclusivity recognition, and market commentary [N1][N2][N6][N8].